Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation

BioDrugs

Volumn 17, Issue 4, 2003, Pages 271-279

  Keown, Paul A ^a,b,e   Balshaw, Robert ^b,c   Khorasheh, Shideh ^b   Chong, Mei ^b   Marra, Carlo ^a   Kalo, Zoltan ^d   Korn, Alex ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Syreon Corporation   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d NOVARTIS PHARMA AG   (Switzerland)

^e VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; RAPAMYCIN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BACTERIAL INFECTION; BINDING AFFINITY; CANCER; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPATHOLOGY; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; MULTICENTER STUDY; MYCOSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT FAILURE; VIRUS INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CLINICAL TRIALS, PHASE III; DATA INTERPRETATION, STATISTICAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTICENTER STUDIES; MYCOPHENOLIC ACID; QUALITY OF HEALTH CARE; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT FUSION PROTEINS; RISK ASSESSMENT; TIME FACTORS;

EID: 0041733081     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317040-00006     Document Type: Article

References (37)

1. Canadian Organ Replacement Registry. Dialysis and renal transplantation (1981-1996): 1998 Report, Vol. 1. Ottawa: Canadian Institute for Health Information. 1998
2. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-30
3. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235-42
4. Dew MA, Switzer GE, Goycoolea JM, et al. Does transplantation produce quality of life benefits? A quantitative analysis of the literature. Transplantation 1997; 64: 1261-73
5. Evans RW, Kitzmann DJ. An economic analysis of renal transplantation. Surg Clin North Am 1998; 78: 149-74
6. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-12
7. Canadian Organ Replacement Registry. Organ donation and transplantation (1981-1996): 1998 Report. Vol. 2. Ottawa: Canadian Institute for Health Information, 1988
8. Feld LG, Stablein D, Fivush B, et al. Renal transplantation in children from 1987-1996: the 1996 Annual Report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 1997; 1: 146-62
9. Keown PA. New immunosuppressive strategies. Curr Opin Nephrol Hypertens 1998; 7: 659-63
10. Keown P, Niese D. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation: International Sandimmun Neoral Study Group. Kidney Int 1998; 54: 938-44
11. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy anaIysis of three randomized, double-blind, clinical studies in prevention of rejection: The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39-47
12. Rush DN, Karpinski ME, Nickerson P, et al. Does subclinical rejection contribute to chronic rejection in renal transplant patients? Clin Transplant 1999; 13: 441-6
13. Ishikawa A, Flechner SM, Goldfarb DA, et al. Quantitative assessment of the first acute rejection as a predictor of renal transplant outcome. Transplantation 1999; 68: 1318-24
14. Humar A, Kerr S, Gillingham KJ, et al. Features of acute rejection that increase risk for chronic rejection. Transplantation 1999; 68: 1200-3
15. Onrust SV, Wiseman LR. Basiliximab. Drugs 1999; 57: 207-13
16. Kovarik JM, Rawlings E, Sweny P, et al. Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients. Transpl Int 1996: 9 Suppl. 1: S32-3
17. Kovarik J, Wolf P, Cisterne JM, et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997; 64: 1701-5
18. Kovarik JM, Moore R, Wolf P, et al. Screening for basiliximab exposure-response relationships in renal allotransplantation. Clin Transplant 1999; 13: 32-8
19. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients: CHIB 201 International Study Group. Lancet 1997; 350: 1193-8
20. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody: United States Simulect® Renal Study Group. Transplantation 1999; 67: 276-84
21. Jacobs P, Bachynsky J, Baladi J-F. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics 1995; 6: 182-9
22. Baladi J-F, Menon D, Otten N. Use of economic evaluation guidelines: 2 years' experience in Canada. Health Econ 1998; 7: 221-7
23. Andersson F. Why is the pharmaceutical industry investing increasing amounts in health economic evaluations? Int J Technol Assess Health Care 1995; 11: 750-61
24. Moher D, Jadad AR, Nichol G, et al. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials 1995; 16: 62-73
25. Ponticelli C, Yussim A, Cambi V, et al. Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine. Transplant Proc 2001; 33: 1009-10
26. Ponticelli C, Yussim A, Cambi V, et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001; 72: 1261-7
27. Lawen JG, Davies EA, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003; 75: 37-43
28. Schulzer M, Mancini GB. 'Unqualified success' and 'unmitigated failure': number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse effects. Int J Epidemiol 1996; 25: 704-12
29. Norman DJ, Kahana L, Stuart FP, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55: 44-50
30. Sollinger H, Kaplan B, Pescovitz MD, et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001; 72: 1915-9
31. MacDonald AS, RAPAMUNE Global Study Group. A worldwide phase III randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-80
32. The RAPAMUNE US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. Lancet 2000l; 356: 194-202
33. Keown PA, Balshaw R, Krueger H, et al. Economic analysis of basiliximab in renal transplantation. Transplantation 2001; 71: 1573-9
34. Parsons DS, Hams DC. A review of quality of life in chronic renal failure. Pharmacoeconomics 1997; 12: 140-60
35. Painter PL, Luetkemeier MJ, Moore GE, et al. Health-related fitness and quality of life in organ transplant recipients. Transplantation 1997; 64: 1795-800
36. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473-81
37. Udvarhelyi IS, Colditz GA, Rai A, et al. Cost-effectiveness and cost-benefit analyses in the medical literature. Ann Intern Med 1992; 116: 238-44